Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting

Abstrakt

Conclusions: Omalizumab use is associated with an OCS-sparing effect in patients with uncontrolled persistent allergic asthma in the real-world setting.

Klíčová slova

• Anti-immunoglobulin E
• Oral corticosteroid use
• Omalizumab
• Registry
• Uncontrolled persistent allergic asthma